Neoadjuvant Therapy With Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report

    April 2023 in “ Heliyon ”
    Hai Huang, Yucong Zhang, Zhi Chen … Chunguang Yang
    Studysummary In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on cell.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Efficacy and Safety of a Novel Anti-HER2 Therapeutic Antibody RC48 in Patients with HER2-Overexpressing, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer: A Single-Arm Phase II Study Cancer Communications · 2021